B cell depletion therapy for patients with systemic lupus erythaematosus results in a significant drop in anticardiolipin antibody titres
B cell depletion therapy for patients with systemic lupus erythaematosus results in a significant drop in anticardiolipin antibody titres
复制标题
DOI：
10.1136/ard.2007.078402
复制
发表时间：
2008-03-01
影响因子：
27.4
通讯作者：
Isenberg, D. A.
中科院分区：
文献类型：
--
作者：
Ioannou, Y.;Lambrianides, A.;Isenberg, D. A.
背景资料：B细胞耗竭疗法（BCDT）最近已成功用于治疗患有类风湿性关节炎和系统性红斑狼疮（SLE）的患者。由于抗磷脂抗体已被牵连的抗磷脂综合征（APS）的发病机制，我们问的问题是否BCDT影响IgG抗心磷脂抗体（ACL）在我们的队列中的32例SLE患者给予此treatment.Methods：我们确定了7例SLE患者谁经历了BCDT，并有至少两个中度阳性ACL滴度至少12周分开。其中只有1例患者发生APS。结果：BCDT后0、6-9个月，IgG aCL水平平均为20.6个标准化IgG抗磷脂单位（GPLU）（范围（SD）10-32，（10.1），正常值5）。在消耗后6-9个月，7名患者中有6名患者的IgG aCL水平检测不到，另1名患者的水平从25 GPLU降至15 GPLU（p
Background: B cell depletion therapy ( BCDT) has recently been used with success to treat patients with rheumatoid arthritis and systemic lupus erythematosus (SLE). As antiphospholipid antibodies have been implicated in the pathogenesis of the antiphospholipid syndrome (APS), we asked the question whether BCDT affects levels of IgG anticardiolipin antibodies (aCL) in our cohort of 32 SLE patients given this treatment.Methods: We identified seven SLE patients who had undergone BCDT and had had at least two moderate positive aCL titres at least 12 weeks apart. Of these only one patient had APS. IgG aCL were measured at time 0 and 6-9 months post BCDT.Results: At time 0, the mean IgG aCL level was 20.6 standardized IgG antiphospholipid units (GPLU) ( range (SD) 10-32, (10.1), normal level,5). At 6-9 months post depletion the IgG aCL levels in six of the seven patients was undetectable and in the other patient the level reduced from 25 GPLU to 15 GPLU (p